Dossier assessment

Rucaparib (maintenance treatment in ovarian cancer after first-line therapy) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A23-134
Last updated

Report documents

  1. Extract of dossier assessment

    Rucaparib (maintenance treatment in ovarian cancer after first-line therapy) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 248 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A23-134_en
  2. Dossier assessment

    Rucaparib (maintenance treatment in ovarian cancer after first-line therapy) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 724 kB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A23-134

Dossier assessment

Indication:

Maintenance treatment of adult patients with advanced (FIGO Stages III and IV) high-grade epithelial ovarian cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy

Result of dossier assessment:

Added benefit not proven

Project details

Project no.
A23-134
Commission
Commission awarded on 14.12.2023 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A23-134_en

Connected Projects

  1. Dossier assessment

    Rucaparib (ovarian, fallopian tube or peritoneal cancer; maintenance treatment) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-23
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Rucaparib (ovarian, fallopian tube or peritoneal cancer; treatment) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-22
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form